|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shoag J and Barbieri CE: Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 18:543–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Williams JL, Greer PA and Squire JA: Recurrent copy number alterations in prostate cancer: An in silico meta-analysis of publicly available genomic data. Cancer Genet. 207:474–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karantanos T, Corn PG and Thompson TC: Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao D and Chen Y: Organoid development in cancer genome discovery. Curr Opin Genet Dev. 30:42–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res. 43:1809–1818. 1983.PubMed/NCBI
|
|
7
|
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:16–23. 1979.PubMed/NCBI
|
|
8
|
Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL and Pienta KJ: VCaP, a cell-based model system of human prostate cancer. In vivo. 15:163–168. 2001.PubMed/NCBI
|
|
9
|
Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC and Logothetis CJ: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 3:2493–2500. 1997.PubMed/NCBI
|
|
10
|
Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 35:403–409. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, et al: Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: A new perspective for an old model. Neoplasia. 9:200–206. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwank G, Andersson-Rolf A, Koo BK, Sasaki N and Clevers H: Generation of BAC transgenic epithelial organoids. PLoS One. 8:e768712013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y and Clevers H: Organoid culture systems for prostate epithelial tissue and prostate cancer tissue. Nat Protoc. 11:347–358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ and Clevers H: Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 459:262–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koo BK, Stange DE, Sato T, Karthaus W, Farin HF, Huch M, van Es JH and Clevers H: Controlled gene expression in primary Lgr5 organoid cultures. Nat Methods. 9:81–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartucci M, Ferrari AC, Kim IY, Ploss A, Yarmush M and Sabaawy HE: Personalized medicine approaches in prostate cancer employing patient derived 3D organoids and humanized mice. Front Cell Dev Biol. 4:642016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M, et al: Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell stem cell. 6:25–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stange DE, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, et al: Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell. 155:357–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sachs N and Clevers H: Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev. 24:68–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, et al: Isolation and in vitro expansion of human colonic stem cells. Nat Med. 17:1225–1227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H and Nishinakamura R: Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell. 14:53–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takasato M, Er PX, Becroft M, Vanslambrouck JM, Stanley EG, Elefanty AG and Little MH: Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol. 16:118–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Antonica F, Kasprzyk DF, Opitz R, Iacovino M, Liao XH, Dumitrescu AM, Refetoff S, Peremans K, Manto M, Kyba M and Costagliola S: Generation of functional thyroid from embryonic stem cells. Nature. 491:66–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koehler KR, Mikosz AM, Molosh AI, Patel D and Hashino E: Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. Nature. 500:217–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, Sekiguchi K, Adachi T and Sasai Y: Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature. 472:51–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP and Knoblich JA: Cerebral organoids model human brain development and microcephaly. Nature. 501:373–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Agarwal S, Hynes PG, Tillman HS, Lake R, Abou-Kheir WG, Fang L, Casey OM, Ameri AH, Martin PL, Yin JJ, et al: Identification of different classes of luminal progenitor cells within prostate tumors. Cell Rep. 13:2147–2158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim J, Koo BK and Knoblich JA: Human organoids: Model systems for human biology and medicine. Nat Rev Mol Cell Biol. 21:571–584. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Velasco S, Kedaigle AJ, Simmons SK, Nash A, Rocha M, Quadrato G, Paulsen B, Nguyen L, Adiconis X and Regev A: Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. Nature. 570:523–527. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, et al: Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 159:163–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, et al: Organoid cultures derived from patients with advanced prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vela I and Chen Y: Prostate cancer organoids: A potential new tool for testing drug sensitivity. Expert Rev Anticancer Ther. 15:261–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, et al: Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 9:24042018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Richards Z, McCray T, Marsili J, Zenner ML, Manlucu JT, Garcia J, Kajdacsy-Balla A, Murray M, Voisine C, Murphy AB, et al: Prostate stroma increases the viability and maintains the branching phenotype of human prostate organoids. iScience. 12:304–317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drost J and Clevers H: Organoids in cancer research. Nat Rev Cancer. 18:407–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elbadawy M, Abugomaa A, Yamawaki H, Usui T and Sasaki K: Development of prostate cancer organoid culture models in basic medicine and translational research. Cancers (Basel). 12:7772020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gleave AM, Ci X, Lin D and Wang Y: A synopsis of prostate organoid methodologies, applications, and limitations. Prostate. 80:518–526. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, et al: A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clin Cancer Res. 24:4332–4345. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Njoroge RN, Unno K, Zhao JC, Naseem AF, Anker JF, McGee WA, Nonn L and Abdulkadir SA: Organoids model distinct vitamin E effects at different stages of prostate cancer evolution. Sci Rep. 7:162852017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Santamaria PG, Moreno-Bueno G, Portillo F and Cano A: EMT: Present and future in clinical oncology. Mol Oncol. 11:718–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J and Witte ON: Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci USA. 113:4482–4487. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al: The genomic complexity of primary human prostate cancer. Nature. 470:214–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JM and Tomlins SA: Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Mod Pathol. 29:157–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T and Rubin MA: The mutational landscape of prostate cancer. Eur Urol. 64:567–576. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, et al: Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 123:4918–4922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, et al: The evolutionary history of lethal metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cheaito K, Bahmad HF, Jalloul H, Hadadeh O, Msheik H, El-Hajj A, Mukherji D, Al-Sayegh M and Abou-Kheir W: Epidermal growth factor is essential for the maintenance of novel prostate epithelial cells isolated from patient-derived organoids. Front Cell Dev Biol. 8:5716772020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bahmad HF, Cheaito K, Chalhoub RM, Hadadeh O, Monzer A, Ballout F, El-Hajj A, Mukherji D, Liu YN, Daoud G and Abou-Kheir W: Sphere-formation assay: Three-dimensional in vitro culturing of prostate cancer stem/progenitor sphere-forming cells. Front Oncol. 8:3472018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nelson JW, Sklenar J, Barnes AP and Minnier J: The START app: A web-based RNAseq analysis and visualization resource. Bioinformatics. 33:447–449. 2017.PubMed/NCBI
|
|
51
|
Edgar R, Domrachev M and Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, Wadi L, Meyer M, Wong J, Xu C, et al: Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, cytoscape and EnrichmentMap. Nat Protoc. 14:482–517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T and Buetow KH: PID: The pathway interaction database. Nucleic Acids Res. 37:D674–D679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Telikicherla D, Navarro JD, Mathivanan S, Pecquet C, et al: NetPath: A public resource of curated signal transduction pathways. Genome Biol. 11:R32010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M and Karp PD: Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 6:R22005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al: Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Res. 39:D691–697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, Guo N, Muruganujan A, Doremieux O, Campbell MJ, et al: The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 33:D284–288. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM and Drake CG: Paucity of PD-L1 expression in prostate cancer: Innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 18:325–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhu YP, Wan FN, Shen YJ, Wang HK, Zhang GM and Ye DW: Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth. Oncotarget. 6:14488–14496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Effron SS, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, et al: CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. Cancer Discov. 9:1538–1555. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Velardi E, Tsai JJ, Radtke S, Cooper K, Argyropoulos KV, Jae-Hung S, Young LF, Lazrak A, Smith OM, Lieberman S, et al: Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med. 24:239–246. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, et al: Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 10:1262011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Peehl DM: Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 12:19–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J, Garber J, et al: Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. Nat Commun. 11:17112020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Donjacour AA, Thomson AA and Cunha GR: FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol. 261:39–54. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yamamoto H, Masters JR, Dasgupta P, Chandra A, Popert R, Freeman A and Ahmed A: CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. PLoS One. 7:e469792012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM and Garraway IP: Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. PLoS One. 7:e342192012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fatehullah A, Tan SH and Barker N: Organoids as an in vitro model of human development and disease. Nat Cell Biol. 18:246–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gjorevski N, Sachs N, Manfrin A, Giger S, Bragina ME, Ordóñez-Morán P, Clevers H and Lutolf MP: Designer matrices for intestinal stem cell and organoid culture. Nature. 539:560–564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Huang Y, Hamana T, Liu J, Wang C, An L, You P, Chang JY, Xu J, Jin C, Zhang Z, et al: Type 2 fibroblast growth factor receptor signaling preserves stemness and prevents differentiation of prostate stem cells from the basal compartment. J Biol Chem. 290:17753–17761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cook C, Vezina CM, Allgeier SH, Shaw A, Yu M, Peterson RE and Bushman W: Noggin is required for normal lobe patterning and ductal budding in the mouse prostate. Dev Biol. 312:217–230. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Bjerke GA, Yang CS, Frierson HF, Paschal BM and Wotton D: Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis. Oncogene. 33:3660–3667. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, Frolov A, Ayala G, Lin X, Feng XH, et al: COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature. 493:236–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, et al: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 470:269–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Franco RD, Mantia EL, Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lu X and Kang Y: Epidermal growth factor signalling and bone metastasis. Br J Cancer. 102:457–461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wang S, Gao D and Chen Y: The potential of organoids in urological cancer research. Nat Rev Urol. 14:401–414. 2017. View Article : Google Scholar : PubMed/NCBI
|
